Notably, FGFR2 expression in murine precancerous lesions correlated with an increase in mutant KRAS signaling. "We know that precancerous pancreatic lesions often carry KRAS mutations," said Tonelli.

Precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations had higher-than-normal expression of the FGFR2 protein, and FGFR2 inactivation ...

Precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations had higher-than-normal expression of the FGFR2 protein, and FGFR2 inactivation ...

SAN DIEGO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, today ...

Led by David Tuveson, PhD, the Roy J. Zuckerberg professor of cancer research and cancer center director at CSHL, the research team analyzed murine and human pancreatic tissue specimens, and found ...

A laboratory on Long Island has found a breakthrough in the fight against pancreatic cancer that can “intercept” its spread.. Now Amy Pollaci, whose father Bill Reindl was diagnosed with stage ...

We discovered that another gene, FGFR2, plays a role in enhancing mutant KRAS signaling in pancreatic cancer. When that happens, those 'early versions' of pancreatic cancer become much more ...

Scientists have found a way to 'intercept' pancreatic cancer. By inhibiting the cancer gene FGFR2, they were able to slow tumor formation. By targeting the FGFR2 and EGFR proteins, they were able ...

FGFR2 fusions or rearrangements occur almost exclusively in iCCA, where they are observed in 10-16 percent of patients 5,6,7. About FIGHT-202 The FIGHT-202 Phase 2, open-label, ...

With the aim of overcoming drug resistance and reducing the toxicities associated with pan-fibroblast growth factor receptor (FGFR) inhibitors, scientists from 3H Pharmaceuticals Co. Ltd. developed a ...